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tivecommons.org/licenses/by-nc-Summary Background: Statins are a class of drugs used to lower cholesterol levels, accom-
panying increased high-density lipoprotein (HDL) levels. Previous studies have suggested that
statins can inhibit inflammation, and also reduce tumor proliferation. We therefore hypothe-
sized that pravastatin, a member of the statins, mediating the inhibitory functions in tumor
growth may be associated with the upregulated HDL constituent, apolipoprotein A1 (ApoA1).
Methods: Pravastatin-induced inhibition in tumor proliferation in vitro and in xenografts was
investigated. Reduced ApoA1 expressions were detected in the tumor regions in specimens
from tumor patients as well in xenografts using Western Blotting. Moreover, ApoA1 was admin-
istered to inhibit tumor proliferation, and pravastatin was given to enhance the chemothera-
peutic efficacy of doxorubicin (DOX).
Results: We found a significant statistical reduction of ApoA1 in the tumor regions of specimens
from gastric cancer and colorectal cancer patients. MKN45 cells proliferation was inhibited by
18% under the growing medium containing pravastatin. ApoA1 levels were elevated in liver
Clone 9 cells administered pravastatin, but not in MKN45 cells. In vitro studies revealed that
ApoA1 can reduce MKN45 tumor proliferation. Moreover, the tumor volume was significantly
reduced in in vivo xenografts after the administration of pravastatin. Combined treatments
of pravastatin with DOX significantly minimized the size of tumors, leading to a better thera-
peutic efficacy.astroenterology, Cheng Hsin General Hospital, Number 45, Cheng Hsin Street, Pai-Tou, Taipei 112,
sion, Number 1000, Wunhua Road, Jiaan Village, Longtan, Taoyuan 325, Taiwan.
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4 C. Yeh et al.Conclusion: This study demonstrated that pravastatin elevated ApoA1, an HDL major constit-
uent with anti-inflammatory characteristics, which displayed strong adversary associations
with tumor developments and growth. Increasing the amounts of ApoA1 by pravastatin coupled
with DOX may improve the therapeutic efficacy for cancer treatment.
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Gastrointestinal tumors including gastric cancer (GC) and
colorectal cancer (CRC) have been well recognized as tu-
mors with high incidence and mortality worldwide [1,2].
Recently, targeted therapy using probing the overexpressed
tumor markers has been demonstrated to have high effi-
ciency in limiting tumor developments. The strategy also
increased diagnostic accuracy in early stages of the above
mentioned cancers [3,4]. In clinical practice, most patients
with GC and CRC are diagnosed in advanced tumor stages
with metastasis. Besides the limited diagnostic tools, it is
urgent to develop and improve the therapeutic efficacy in
tumor treatments. The poor prognosis of GC and CRC re-
sults from the lack of efficient therapeutic strategies.
Statins are used for lowering plasma cholesterol levels as
drugs treating coronary heart disease in clinical practice.
The rationale of these agents is that they are competitive
inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase in the mevalonate pathway [5]. In addition to
cholesterol lowering effects, statins have been well studied
for their antitumor characteristics. For example, statins,
except pravastatin, can inhibit breast tumor cell prolifera-
tion in vitro [6]. Moreover, a previous study has revealed
that three kinds of statins including simvastatin, lovastatin,
and pravastatin, can all inhibit esophageal adenocarcinoma
cell proliferation through reducing farnesylation in protein
targets such as Ras [7], indicating that statins have potential
to aid chemotherapeutic agents in such tumor therapy.
Because we noticed that the antitumor effects of statins are
dependent on the types of tumors and importantly, on the
performed statin dose [8,9], we are dedicated to discovering
the antitumor mechanism of statins.
In this study, we aimed to evaluate the tumor inhibitory
effect of pravastatin, and to discover apolipoprotein A1
(ApoA1) as one of the putative tumor markers in gastroin-
testinal cancers. To our knowledge, statins can increase
high-density lipoprotein (HDL) in serum [10] which pos-
sesses anti-inflammatory functions [11e13]. The most
abundant component in HDL is ApoA1. A previous study has
indicated that ApoA1 displays anti-inflammatory and anti-
oxidant properties [14], revealing that ApoA1 may be an
antitumor agent. Moreover, ApoA1 inhibits tumor cell pro-
liferation in vitro, and reduces tumor growth in vivo in
transgenic tumor models expressing ApoA1 [15,16]. It has
been well documented that ApoA1 reduces the functions of
activated neutrophils [17,18], and then diminishes the
tumor cell proliferation due to neutrophils participation in
tumor proliferation and metastasis [19]. Therefore, ApoA1is expected to have antitumor effects through binding to
lipidic growth factors and reducing inflammation derived
from lymphocytes [15,16,18].
Our previous study indicated that ApoA1 levels were
statistically decreased in the tumor regions of GC patients’
specimens using a proteomic two-dimensional difference
gel electrophoresis technique [4]. We are therefore inter-
ested in dissecting the correlations of ApoA1 and tumori-
genesis. To reboot the ApoA1 level, pravastatin was used
and its antitumor effects were characterized and assessed.
A previous study demonstrated that pravastatin slightly in-
hibits tumor cell proliferations [20], and significantly sup-
presses tumor growth in animal xenografts [9], concluding
that pravastatin may have indirect effects on tumor pro-
liferation. Moreover, another previous study demonstrated
that ApoA1 decreases in larger tumors compared to that in
smaller tumors in xenograft models, suggesting that ApoA1
is a downregulated marker of GC [21]. Moreover, the lower
ApoA1 levels are associated with the tumor growth [20].
Therefore, increasing the ApoA1 levels in patients with GC
may benefit the tumor therapy. We therefore administrated
pravastatin to tumor xenografts to increase the ApoA1
levels, and to benefit the doxorubicin (DOX) chemotherapy,
because statins have been demonstrated to synergize with
DOX in ovarian cancer [22].
In order to improve the therapeutic efficiency of GC and
CRC, this study specifically assumed biomarkers as a
promising therapeutic strategy. Therefore, ApoA1 was
investigated in this study as the biomarker of GC and CRC.
We performed ApoA1 to inhibit tumor cell proliferation,
and also elucidated that ApoA1 functioned to reduce tumor
growth. Furthermore, the treatment combined with pra-
vastatin and DOX largely reduced tumor volume in tumor
xenografts. The pravastatin-mediated antitumor effects
may be associated with the increased amount of ApoA1. In
conclusion, the targeted therapy for suppressing inflam-
mation through increasing ApoA1 by pravastatin may be
promising for tumor treatment.Materials and methods
Acquisition of the tissues of GC and CRC
This study and acquisition of the clinical samples were
granted and approved by the Institutional Review Board of
Cheng Hsin General Hospital [CHGH-IRB-(240) 100-01]. The
pairs of GC (n Z 9) and CRC specimens (n Z 17) including
tumors (T) and adjacent nontumors (NT) were surgically
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the collected samples were determined by a pathologist
using histological staining examination. We only included
adenocarcinoma types of GC and CRC patients without
metastasis in the experimental analysis. Tumor grades were
determined according to the American Joint Commission
on Cancer Staging system.
Cell lines
GC MKN45 cells and rat liver Clone9 cells derived from the
normal liver of a 4-week-old Sprague-Dawley male rat [23]
were cultured in 10 mL of Dulbecco’s Modified Eagle Me-
dium (DMEM) medium with 10% fetal bovine serum (FBS) and
1% antibiotics (mixture of 100 U/mL of penicillin and 100 mg/
mL of streptomycin) in a 5% CO2, 37
C incubator for 48 hours.
Western blotting
To investigate the ApoA1 expression in tumor tissues of GC
and CRC, the T and NT regions from the paired specimens
were first differentiated and captured. These pairs of tissue
samples were homogenized (Pro 200; Bertec, Oxford, Con-
necticut, USA) in lysis buffer (10mM of sodium phosphate,
0.9% sodium chloride, and 1% triton-X100, pH 7.4) and
incubated on shaking at 4C for 1 hour. After getting rid of
the precipitated pellets by centrifugation (10,000 rpm, 5
minutes), the supernatants were added with the same
volume of sample buffer (10mM of sodium phosphate, 0.9%
sodium chloride, 8M of urea, 30% glycerol, 2% sodium
dodecyl sulfate, 0.1% b-mercaptoethanol, and 0.1% bro-
mophenol blue), and boiled at 100C for 5 minutes.
Approximately 20 mg of each sample protein from MKN45
or Clone 9 cells treated with pravastatin were loaded onto
the individual grid of 4e12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE; Invi-
trogen). The iblot dry blotting system (Invitrogen, Wal-
tham, Massachusetts, USA) was used to transform the
proteins to a polyvinylidene fluoride membrane based on
ion flowing along with a copper electrode. After using 0.5%
milk to blot the polyvinylidene fluoride membrane for 30
minutes, the primary antibody (2 mg/mL) produced in
chicken detecting ApoA1 (Sigma Aldrich, St. Louis, Missouri,
USA) was added for 2 hours incubation on a shaker. The
secondary antibodies conjugated with horseradish peroxi-
dase against chicken (2 mg/mL) were then added and
incubated with membranes for 1 hour under smooth shaking
conditions at room temperature. During the incubating
processes, membranes were washed three times using PBS
buffer (10mM sodium phosphate, pH 7.4 and 0.9% sodium
chloride). To trace the protein expression, the enhanced
chemiluminescence (ECL) detection system (Merck Milli-
pore, Billerica, Massachusetts, USA) was performed, and
images were acquired by Imaging System (Gel Doc XR Sys-
tem; Bio-Rad, Hercules, California, USA) under the mod-
erate exploring time.
In vitro tumor inhibition assay
The cell viabilities of MKN45 cells treated with ApoA1
(Sigma Aldrich), DOX (Sigma Aldrich), or pravastatin (SigmaAldrich) were measured and confirmed using the tetrazo-
lium salt WST-1 assay [2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-2,4-disulfophenyl]-2H-tetrazolium (Takara, Mountain
View, CA, USA). Attached instructions were followed for the
WST-1 measuring process. Each well of a 96-well microplate
contained 2  104 cells in 100 mL of culture medium, and
there were at least five replicates. A dose-dependent
manner was performed to investigate the antitumor ef-
fects of pravastatin (1 mg/mL, 5 mg/mL, 10 mg/mL) or DOX
(3 mg/mL, 6 mg/mL, 12 mg/mL, 24 mg/mL) for 24 hours
treatment. Meanwhile, the positive and negative controls
used 2% Triton X-100 and no addition, respectively, for
calculating the percentage of cell viability after agent
treatments. Moreover, 1 mg/mL, 10 mg/mL, and 100 mg/mL
of lysophosphatidate (LPA; Sigma Aldrich) for 24 hours
treatment were also investigated for enhancing the tumor
cell proliferation, whereas ApoA1 alone (100 mg/mL
selected according to the dose applied previously [15]) or
LPA (10 mg/mL) combined with ApoA1 (100 mg/mL) for 24
hours treatment were also analyzed to investigate the
possible mechanism of ApoA1 in tumor inhibition.
In vivo tumor inhibition assay
Male nude mice were obtained from the National Labora-
tory Animal Center, Taiwan. The 8-week-old mice were
selected and housed in a 12-hour light cycle at 22C, and
given food (mouse standard diet) or water ad libitum. All
animal studies were approved by the institutive ethical
review committee and were carried out in accordance with
ROC of Taiwan government regulations and NIH guidelines
on the care and welfare of laboratory animals. The gastric
tumor xenografts were established by injecting 2  106 of
GC MKN45 cells into the subcutaneous legs of nude mice
aged 6e8 weeks. The tumor therapeutic experiments were
performed after 6 days from tumor cells injection to
establish the tumor xenograft model, and the average of
the tumor size was w40 mm3. For tumor therapy, DOX,
pravastatin, or a combination of both agents was injected
via the tail vein with 5 mg/kg DOX and 100 mg of pravastatin
(n Z 3 for each group) at Day 6, Day 9, and Day 12 after
tumor implantation. The tumor volume was calculated
using the following formula: length  width2  0.52.
Statistical analysis
The statistic software GraphPad Prism 5 (GraphPad Soft-
ware, Inc., La Jolla, California, USA) was used to calculate
the differential significance using Bonferroni’s multiple
comparison test. The significance difference was accept-
able at p < 0.05.
Results
ApoA1 decreased in the tumor tissues of the
patients with GC and CRC
ApoA1 has been reported to be an acute phase-responded
protein, which was reduced in inflammation or tumorigen-
esis [15]. In our previous study, we observed decreased
6 C. Yeh et al.ApoA1 levels in the tissues of GC [4]. As we know, ApoA1 is a
serum protein produced by the liver. In this study, the
collected tissues were immersed in PBS buffer first for
removal of blood and serum protein. Then, we performed
Western blotting for detecting the ApoA1 levels in GC and
CRC tissues. In total, we analyzed nine pairs of GC samples
and 17 pairs of CRC samples; both experiments included
tumor tissues (T) and adjacent normal ones (NT). The re-
sults indicated that ApoA1 levels were reduced in the tumor
tissues of GC (Figures 1A and 1B) and CRC (Figures 1C and
1D) compared to the corresponding normal tissues
(p < 0.05). Moreover, ApoA1 decreased significantly in the
advanced stage of CRC (III/IV) compared to that in the early
stage (I/II) (Figure 1D, p < 0.01), indicating that ApoA1 was
a downregulated marker.
ApoA1 inhibited tumor growth through reducing
LPA function
To evaluate the effects of ApoA1 on tumor inhibition, we
cultured MKN45 tumor cells in the medium containing
ApoA1. This demonstrated that ApoA1 suppressed the
growth of MKN45 cells (Figures 2A and 2B). ApoA1 is a lipid
binding protein and can chelate the lipidic growth factors
and impair their normal functions, leading to inhibition of
tumor growth. LPA is a type of serum-derived lipid growth
factor. This bioactive lipid phosphate is present outside the
cell and signals through a series of cell surface receptors
leading to cell division, survival, and migration. Due to the
specific bioactive roles of LPA, it may be one of the can-
didates bound by ApoA1 and then be depleted in serum.
The results demonstrated that cell viability of MKN45 cells
was increased to 25% and 75% in the medium supplemented
with 10 mg/mL and 100 mg/mL of LPA, respectively
(Figure 2C). Addition of ApoA1 suppressed the cell viability
of MKN45 cells by 50% in the medium containing LPA
(Figure 2D), indicating that ApoA1 inhibited tumor growth
by abrogating lipidic growth LPA-induced cell proliferation.Figure 1 Lower apolipoprotein A1 (ApoA1) expression in the tiss
(CRC). Each 20 mg of tissue protein from GC (nZ 9) and CRC (nZ 17
was used as an internal control. The results demonstrated that Ap
Moreover, the ApoA1 ratio of tumor (T) to nontumor (NT) was lower
(I/II), indicating that ApoA1 was downregulated and associated wiPravastatin induced ApoA1 expression in liver
Clone 9 cells, but not in gastric MKN45 cells in vitro
Pravastatin is one kind of the statins and contributes to
lower cholesterol through two pathways: (1) pravastatin as
a reversible competitive inhibitor inhibits the normal
physiological function of HMG-CoA reductase; and (2) pra-
vastatin increases the amounts of HDL which is constituted
by ApoA1 as the major compound. Recently, statins were
suggested to have antitumor characteristics [22,24,25].
Herein, we hypothesized that pravastatin-induced tumor
inhibition may result from rebooting the ApoA1 levels,
contributing to reshaping the inflammatory tumor micro-
environment and favor in the process of anti-tumorigenesis.
To assess our hypothesis, the ApoA1 levels in GC MKN45
cells and liver Clone 9 cells after administration of pra-
vastatin were measured and compared. We observed that
1mM and 5mM of pravastatin induced ApoA1 levels in liver
Clone 9 cells (Figure 3B), but not in GC MKN45 cells
(Figure 3A) compared to the cells without treatment. The
results revealed that pravastatin triggered ApoA1 produc-
tion in liver.
Pravastatin inhibited tumor growth, and enhanced
the chemotherapeutic effect of DOX
In order to investigate the antitumor ability of pravastatin,
we cultured and treated MKN45 cells with pravastatin. The
results demonstrated that pravastatin slightly inhibited the
MKN45 tumor cell growth in vitro using a dose-dependent
method (Figure 4A). The cell viability decreased by 18% in
cells treated with 10mM of pravastatin compared to the
group without any treatments in the control group
(Figure 4A). Furthermore, DOX reduced the MKN45 cell
viability in a dose-dependent manner (Figure 4B), whereas
cell viability was reduced by 63% in medium containing 6mM
of DOX. However, an additional 10mM of pravastatin into
medium containing 6mM of DOX did not gain any extraues of (A, B) gastric cancer (GC) and (CeE) colorectal cancer
) was loaded and analyzed in Western Blotting, whereas b-actin
oA1 levels were decreased both in the tissues of GC and CRC.
in advanced stage (III/IV) CRC compared to that in earlier stage
th tumor stage. * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 2 Apolipoprotein A1 (ApoA1) in vitro reduced the cell proliferation of MKN45 cells through inhibiting the tumor-enhanced
lysophosphatidate (LPA). (A) The 100 mg/mL of ApoA1 was treated with the MKN45 cells for 24 hours incubation. The amount of
MKN45 cells decreased compared to that without ApoA1 treatment observed under a microscopy. (B) The decreased cell viability of
MKN45 cells in the ApoA1-treated group (100 mg/mL) was demonstrated compared to the nonadditive group. (C) LPA, a lipidic
growth factor, was administrated to induce MKN45 cell proliferation in a dose-dependent manner. (D) LPA (10 mg/mL), ApoA1
(100 mg/mL), and a combination of both agents were administrated and compared, whereas ApoA1 was added to inhibit LPA-
induced growing effect. The results revealed that ApoA1 directly inhibited the cell viability in MKN45 cells and indirectly
blocked LPA function in vitro. Scale bar, 500 mm. * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 3 Pravastatin increased apolipoprotein A1 (ApoA1)
levels in liver Clone9 cells, but not in gastric MKN45 cells. (A)
Equivalent expressions of ApoA1 were observed in gastric
MKN45 cells treated with or without 1mM of pravastatin
analyzed using Western blots. (B) Higher ApoA1 levels in 1 or
5mM of pravastatin-treated liver Clone9 cells were observed
compared to the cells without treatment. The results indicated
that pravastatin increased ApoA1 only in normal liver cells, but
not in tumor MKN45 cells. ** p < 0.01. NS Z not significant.
Pravastatin inhibits tumor through elevating ApoA1 7therapeutic effects (p > 0.05, Figure 4C). The results
indicated that pravastatin decreased MKN45 cell viability by
18% (Figure 4A) similar to the result combined with DOX
in vitro (15%) (Figure 4C).
In order to investigate the therapeutic effects of pra-
vastatin, we intravenously injected 100 mg of pravastatin
into each MKN45-induced GC xenograft via tail veins. To
assess additional beneficial effects of pravastatin, the
combined drugs including pravastatin and DOX were
administrated into xenografts. The results illustrated that
pravastatin inhibited the tumor growth in MKN45-induced
xenografts in vivo (Figure 5). We also demonstrated that
DOX reduced tumor growth compared to the PBS group
(Figure 5). Moreover, the combination of pravastatin and
DOX enhanced the antitumor effect compared to pravas-
tatin or DOX alone (Figure 5). Therefore, the combination
of pravastatin and DOX had a higher inhibitory effect
(Figure 5). The results demonstrated that pravastatin may
be an effective adjuvant for DOX.Discussion
This study aimed to evaluate the inhibitory effect of pra-
vastatin on tumor growth and progression, and tried to
Figure 4 Pravastatin did not enhance doxorubicin (DOX) effect in vitro. (A) Pravastatin (Prava) was administrated in MKN45 cells
using a dose-dependent manner to investigate the antitumor effect. The 10mM of pravastatin only slightly reduced MKN45 cell
viability by 18% compared to the normal group (Ctrl). (B) DOX was administrated and demonstrated inhibitory effects on MKN45
cells in a dose-dependent method (p < 0.001), whereas 6mM of DOX led to a 63% decrease of cell viability. (C) Pravastatin (10mM) did
not enhance DOX therapeutic effect in vitro, only leading to decrease by 15% which was similar to the administration of pravastatin
alone. * p < 0.05. NS Z not significant.
8 C. Yeh et al.uncover the molecular mechanism of pravastatin in tumor
therapy. Because pravastatin is a HDL inducer [26,27], in
HDL the major component is ApoA1, we therefore measured
the pravastatin-induced ApoA1 expression and evaluated
the pravastatin-induced antitumor effect. ApoA1 has been
reported to have the capacity to inhibit tumor growth
through binding to lipidic growth factors [15] and sup-
pressing neutrophil activity [17,18,28] which may modulateFigure 5 Pravastatin reduced tumor growth and enhanced the
including phosphate-buffered saline (PBS) (n Z 3), pravastatin (10
nZ 3), and pravastatin combined DOX (nZ 3) were administrated
at Day 6, Day 9, Day 12, Day 15, and Day 18 after tumor impla
significantly reduced tumor growth compared to the PBS group,
inhibitory effect, revealing that pravastatin enhanced DOX theraptumor development. In this study, we demonstrated that
pravastatin not only elevated ApoA1 levels and inhibited
tumor growth, but also benefited the DOX inhibitory effect
in vivo.
Previous studies have demonstrated that ApoA1 is
downregulated as a biomarker in tumors such as ovarian
cancer [29] and GC [4,21]. Moreover, transgenic mice
expressing ApoA1 result in tumor inhibition, suggesting thatinhibitory effect of doxorubicin (DOX) in vivo. Four groups
0 mg injection/mouse, n Z 3), DOX (5 mg/kg injection/mouse,
and compared. The tumor volume of each mouse was measured
ntation. The results indicated that both pravastatin and DOX
whereas pravastatin combined with DOX led to higher tumor
eutic effects in MKN45-induced xenografts. * p < 0.05.
Pravastatin inhibits tumor through elevating ApoA1 9ApoA1 suppresses tumor cell proliferation. Therefore, the
increase of ApoA1 was expected to reduce the tumor
growth, which could be achieved by pravastatin demon-
strated in this study. ApoA1 is the major component of HDL,
participating in cholesterol and phospholipids transport;
therefore, it was suggested to remove tumor-proliferated
lipidic growth factors for tumor treatment. In addition to
the capability of ApoA1 to inhibit the lipidic growth factors
in tumors, it has been suggested to abrogate the activity of
neutrophils participating in tumor development [30,31].
Therefore, we hypothesized that rebooting the amounts of
ApoA1 levels can inhibit tumor growth, even to enhance the
chemotherapeutic efficacy of DOX.
The results of the tumor-inhibitory assay demonstrated
that pravastatin reduced the tumor growth as a therapeutic
agent [11,24]. A previous study has indicated that statins
can inhibit cell proliferation and induce apoptosis in
esophageal adenocarcinoma cells through inhibiting Ras
farnesylation and ERK/Akt signaling pathways [7], which is
a direct tumor inhibitory mechanism of statins. Beside this
tumor-inhibitory mechanism, we further investigate other
possible mechanisms of pravastatin in inhibiting tumor
growth. Moreover, pravastatin was used to enhance the
chemotherapeutic effect of DOX in this study. We found
that pravastatin increased amounts of ApoA1 in MKN45-
induced tumor xenografts detected using Western Blotting
(data not shown). Because ApoA1 is a serum protein
secreted from the liver, the antitumor characteristic of
ApoA1 is of interest [14,15]. Therefore, we speculated that
pravastatin-induced increases in the levels of ApoA1 may
rationally shed a new therapeutic route for tumor treat-
ment in GC and CRC patients. In the serum of GC xeno-
grafts, we found that ApoA1 decreased as a downregulated
protein after MKN45 cells embedded, which was consistent
with the previous study [32]. Moreover, we discovered that
pravastatin increased the ApoA1 levels in liver Clone 9
cells, and inhibited tumor growth in vivo. Pravastatin has
been reported to function in inhibiting tumor growth
[20,24]. This study investigates the molecular mechanism
of the pravastatin-induced antitumor effect. The in vitro
assay revealed that the antitumor ability of pure ApoA1
protein was through inhibiting LPA-induced tumor prolifer-
ation. Therefore, pravastatin reducing tumor growth may
result from the increased amount of ApoA1 in serum.
Hence, the increase of ApoA1 was demonstrated as a
promising strategy for inhibiting tumors and enhancing DOX
efficacy.
The antitumor mechanisms of ApoA1 are reported to
bind and reduce the effect of proinflammatory phospho-
lipids such as LPA on tumor proliferation [15]. ApoA1 can
also inhibit inflammation [14,28,33] derived from tumor-
associated neutrophils. To our knowledge, ApoA1 is the
major constitutive protein of HDL in transporting choles-
terol and phospholipids from peripheral cells to the liver.
However, ApoA1 levels were decreased in the tumors,
leading to the increase of phospholipid-induced tumori-
genesis and enhancement of the neutrophil activity. ApoA1
demonstrated anti-inflammatory and antitumor effects,
whereas the increase of ApoA1 may be an antitumor
strategy. Therefore, ApoA1 mimetic peptides were created
against tumors such as L-4F and D-4F in ovarian cancer [15]
and colon cancer [11]. Moreover, the ApoA1 mimeticpeptide can also be applied to inhibit atherosclerosis in an
ApoE-null mouse model [34]. In this study, our primary re-
sults revealed that ApoA1 reduced the cell viability of
MKN45 cells in vitro, and also inhibited LPA-induced tumor
cell proliferation, indicating that ApoA1 may be an anti-
tumor protein. Therefore, the induction of ApoA1 in tumor-
burdened mice by pravastatin can reduce the tumor growth
and benefit the DOX effect.
In conclusion, we first evaluated the decreased expres-
sion of ApoA1 in GC and CRC tissues, and pravastatin
rebooted the ApoA1, leading to inhibition of tumor cell
growth. In addition to lower cholesterol, pravastatin can
also suppress tumor growth in vivo by enhancing ApoA1
levels in the MKN45-induced xenografts. In this study, we
demonstrated that the strategy of rebooting ApoA1 by
pravastatin coupled with the chemotherapeutics of DOX is a
potential therapy for patients with cancer.
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